Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

45.56 -0.32 (-0.70%)
Streaming Delayed Price Updated: 11:07 AM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amphastar Pharma

< Previous 1 2 Next >
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
Via ACCESSWIRE
Lilly to Divest BAQSIMI to Amphastar
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022
Via ACCESSWIRE
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Via ACCESSWIRE
Promising Small Biotech Amphastar Sees Actionable Pullback
Small-cap Amphastar Pharmaceuticals is pulling back from recent highs in an orderly fashion, potentially offering a new entry point after beating Q1 views. 
Via MarketBeat
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022
Via ACCESSWIRE
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
Via ACCESSWIRE
Amphastar Receives FDA Approval for Vasopressin
Via ACCESSWIRE
Amphastar Receives FDA Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
Amphastar Receives FDA Approval for Regadenoson
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022
Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.